Authors
Loading...
Policy review uncovers regulatory and patent mechanisms limiting generic insulin in the United States, highlighting enduring market barriers affecting diabetes care.
Greene et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: